Effect of concomitant rifampin and clarithromycin on elexacaftor-tezacaftor-ivacaftor using a PBPK modeling approach
{{output}}
Background: Rifampin (RIF) is first-line therapy for Mycobacterium avium complex (MAC) in people with cystic fibrosis (CF); but it induces CYP3A, causing significant drug - drug interactions (DDIs) with elexacaftor/tezacaftor/iva... ...
